CELLCEPT pdr 200 mg/ml pour susp fl 175 ml
7680547010125
CH-54701
L04AA06
07.15.0.
Reimbursement limitations:
CELLCEPT
Adultes avec troubles de la déglutition, enfants et adolescents de 1 à 18 ans uniquement …
1 / 3
google
Details
- Product number
- 5470101
- CPT
- -
- Packaging group
- 1 x 35 g
- Unit
- Flasche(n)
- Composition
- mofetili mycophenolas 200 mg, lecithinum ex soja, arom.: vanillinum et alia, aspartamum, sorbitolum, conserv.: E 218, excipiens ad pulverem corresp. suspensio reconstituta 1 ml.
Articles (1)
Cellcept, Pulver zur Herstellung einer Suspension zum Einnehmen
Pulver zur Herstellung einer Suspension zum Einnehmen
1 x 35 g
Official Swissmedic V2 data
Additional information from the official database
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
200.0 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | AIMDK |
|
(N/A)
|
- | Substance | AIMDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | Konservierungsstoff (Conservateur) |
Reimbursement information
Public price
CHF 177.55
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
01/07/2002
Authorization holder
Roche Pharma (Schweiz) AG
4058 Basel
Authorization information
- Swissmedic authorization number
- 54701
- Drug name
- Cellcept, Pulver zur Herstellung einer Suspension zum Einnehmen
- Galenic form
- PULS
- ATC Code
- L04AA06
- Authorization status
- Z
- Dispensation category
- B
- First authorization
- 14/06/1999
- Authorization expiration date
- 31/12/9999
- IT number
- 07.15.0.
- Domain
- Human medicine
Packaging details
- Description (FR)
- CELLCEPT pdr 200 mg/ml pour susp fl 175 ml
- Description (DE)
- CELLCEPT Pulv 200 mg/ml für Susp Fl 175 ml
- Market launch
- 14/06/1999
- Narcotic (BTM)
- No